Patients
Tumors, nausea and vomiting, toxicity
DISEASE PROGRESSION, DISEASE, TUMORS, ONCOLOGY, DRUG INTERACTIONS
Eligible patients were ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and measurable or non-measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) [Exclusion criteria included, but were not limited to: use of anticancer drugs within 21 days or 5 half-lives, whichever was shorter, prior to the first adavosertib dose, with a minimum of 10 days between termination of the prior treatment and administration of adavosertib treatment.Antiemetic prophylaxis was mandatory. Prior to each adavosertib dose, patients received an oral serotonin 5-HT3 antagonist: ondansetron 8 mg bid or granisetron 1 mg bid. For patients receiving the qd dosing schedule, a second dose of antiemetics could be administered 8 h later if nausea and vomiting continued. Oral dexamethasone 4 mg was given on day 1 of each adavosertib dosing period, unless contraindicated or not well tolerated. Aprepitant and fosaprepitant were not permitted because of known drug–drug interactions.Patients could continue adavosertib treatment until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.An independent ethics committee/institutional review board approved the final clinical study protocol, including the final version of the informed consent form and any other written information provided to participants. All participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation, good clinical practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics [